Articles tagged with: Treanda
News»

The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.
More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell disorders”).
The …
News»

Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.
The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.
MLN9708
During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented results from a Phase 1 study of …
News»

Yesterday was the first day of the American Society of Hematology (ASH) 2011 annual meeting, which is being held in San Diego.
Although the day featured no oral presentations of new myeloma-related research, it started with an interesting educational session focused on multiple myeloma.
There also were a number of poster presentations during the day summarizing important new research findings.
The educational session in the morning featured three presentations by leading myeloma specialists.
Induction Therapy And Maintenance Treatment
The first presentation was by Dr. Donna Reece of the Princess Margaret Hospital in …
News»

The results of a recent French analysis indicate that the cancer drug Treanda, in combination with prednisone or dexamethasone, may be effective in relapsed and refractory multiple myeloma patients.
Based on their findings, the French researchers recommended that Treanda (bendamustine) be considered as a treatment option for patients with advanced multiple myeloma.
Treanda is an alkylating agent, which causes cancer cell death by damaging the cancer cells’ DNA. The drug, which was originally developed in East Germany in the 1960s, is currently approved by the FDA to treat certain types of leukemia …
News»

Results of a Phase 1 clinical trial suggest that the cancer drug Treanda, in combination with Revlimid and dexamethasone, is highly active and well tolerated in relapsed and refractory multiple myeloma patients.
Dr. Suzanne Lentzsch, of the University of Pittsburgh School of Medicine and Cancer Institute, presented the results of the study at the American Society of Hematology (ASH) 2010 annual meeting in Orlando.
Based on the safety of the Treanda, Revlimid, dexamethasone regimen observed in this study, Dr. Lentzsch believes that this combination may be particularly well suited for older patients …
News»

Tuesday was the last day of the American Society of Hematology annual meeting in Orlando. The myeloma portion of the conference concluded with one session of talks in the morning about treatments under development.
The first talk was given by Dr. David Siegel of Hackensack University Medical Center in New Jersey. Dr. Siegel presented results from a study of single-agent carfilzomib in myeloma patients who had relapsed multiple times and did not respond to their last treatment (abstract).
Among the 257 evaluable participants, 24 percent achieved at least a partial …
NewsFlash »
Fred Hutchinson Cancer Center To Field Questions At The Beacon's Forums This Week – Dr. William Bensinger, myeloma expert at the Fred Hutchinson Cancer Center in Seattle, WA, will be be responding to medical questions posted in the Myeloma Beacon's forums this week. Readers who have not yet visited the Beacon's new myeloma discussion forums are encouraged to do so, as they already contain a number of informative postings about topics such as myeloma treatment options, managing treatment side effects, and alternative myeloma therapies.
Treanda Combination Therapy Enters Phase 1B/2 Trial For Multiple Myeloma – Last week, the Multiple Myeloma Research Consortium (MMRC) announced the start of a Phase 1B/2 clinical trial that will evaluate a combination of Treanda (bendamustine), Revlimid (lenalidomide) and dexamethasone (Decadron) in relapsed multiple myeloma patients. Treanda is already approved in Germany in combination with prednisone for the treatment of multiple myeloma. In the United States, the drug is approved for the treatment of chronic lymphocytic leukemia and certain lymphomas. For more information, see the MMRC press release or the clinical trial description.
MMRF Kicks Off Race For Research 5K Walk/Run Series – On April 25, the Multiple Myeloma Research Foundation (MMRF) will kick off its annual Race For Research 5K Walk/Run series to raise awareness and funds for multiple myeloma research. The events will take place in eight cities across the Unites States. The first one is scheduled for April 25 in San Francisco. For more information and registration details, see the MMRF Web site.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.